Skip to main navigation Skip to search Skip to main content

Development and characterization of solid lipid nanoparticles loaded with a highly active doxorubicin derivative

  • Barbara Stella
  • , Elena Peira
  • , Chiara Dianzani
  • , Marina Gallarate
  • , Luigi Battaglia
  • , Casimiro Luca Gigliotti
  • , Elena Boggio
  • , Umberto Dianzani
  • , Franco Dosio

Research output: Contribution to journalArticlepeer-review

Abstract

Solid lipid nanoparticles (SLNs) comprise a versatile drug delivery system that has been developed for the treatment of a variety of diseases. The present study will investigate the feasibility of entrapping an active doxorubicin prodrug (a squalenoyl-derivative) in SLNs. The doxorubicin derivative-loaded SLNs are spherically shaped, have a mean diameter of 300–400 nm and show 85% w/w drug entrapment efficiency. The effects on cell growth of loaded SLNs, free doxorubicin and the prodrug have been examined using cytotoxicity and colony-forming assays in both human ovarian cancer line A2780 wild-type and doxorubicin-resistant cells. Further assessments as to the treatment’s ability to induce cell death by apoptosis have been carried out by analyzing annexin-V staining and the activation of caspase-3. The in vitro data demonstrate that the delivery of the squalenoyl-doxorubicin derivative by SLNs increases its cytotoxic activity, as well as its apoptosis effect. This effect was particularly evident in doxorubicin-resistant cells.

Original languageEnglish
Article number110
JournalNanomaterials
Volume8
Issue number2
DOIs
Publication statusPublished - 16 Feb 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Anticancer agent
  • Anticancer prodrugs
  • Doxorubicin
  • Nanoassemblies
  • Solid lipid nanoparticles

Fingerprint

Dive into the research topics of 'Development and characterization of solid lipid nanoparticles loaded with a highly active doxorubicin derivative'. Together they form a unique fingerprint.

Cite this